Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

span class="xn-money">$28.6 million, or $0.62 per share, compared with a net loss of $33.8 million, or $0.87 per share, in 2008.  Net loss for the full year was $116.0 million, or $2.62 per share, compared with a net loss of $106.5 million, or $2.73 per share, in 2008.    

As of December 31, 2009, InterMune had cash, cash equivalents and available-for-sale securities of approximately $99.6 million, which does not include net proceeds of $106.8 million from the public offering completed on January 29, 2010.

Accelerated DOJ Payment

As prescribed in the company's 2006 Settlement Agreement with the Department of Justice (DOJ), InterMune made an accelerated payment to the DOJ in early 2010 of approximately $9.2 million. As a result, the balance of the company's liability under the settlement is satisfied and no further payments will be due pursuant to the Settlement Agreement.  

Financial Guidance for 2010

Due to the significant pirfenidone-related regulatory events anticipated in the first half of 2010, InterMune currently expects to provide forward-looking financial guidance for 2010 following completion of those events.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year 2009, and forward-looking information regarding upcoming milestones in 2010.  Interested investors and others may participate in the conference call by dialing 88
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... -- Hill-Rom (NYSE: HRC ) today announced a ... WA ), the nation,s third largest not-for-profit health ... as Hill-Rom now becomes Providence Health,s sole-source provider of ... surface products. Providence Health is one ... operates 34 hospitals, 475 physician clinics, 22 long-term care ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... , Sept. 23, 2014   COTA, Inc. ... planned $7 million Series A funding round led by ... COTA is the first big data platform designed by ... cost analysis for cancer care in support of healthcare,s ... used to expand development of the COTA platform, hire ...
Breaking Medicine Technology:Hill-Rom Announces Seven-Year, Sole-Source Contract with Providence Health 2Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
... March, 9, 2007-Active Biotech (ACTI.ST), today,announced new positive clinical ... treatment of prostate cancer. , By step-wise dose escalation, ... which corresponds to a doubling of the previously,reported maximum ... a step-wise intra-patient dose-escalation enables a dose,of 1 mg/day ...
... DENVER--(BUSINESS WIRE)--Mar 12, 2007 - Ceragenix Pharmaceuticals,Inc. ... and dermatology, today announced that a catheter,treated ... biofilm,formation in a 21 day study., In ... soaked daily in a phosphate-suffered solution along ...
Cached Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:9/23/2014)... (PRWEB) September 23, 2014 What ... The National Quality Forum (NQF) released a ... http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( http://bit.ly/1tX3lzA ) ... cost of healthcare, how patients define affordability, and ... to get the best possible healthcare at the ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 ... on Manhattan’s Upper West Side that embodies the ... Inhabiting Eden: Christians, Scripture and the Ecological Crisis, ... A. B. Rhodes Professor Emerita of Old Testament ... Bible for ancient wisdom that lends insight into ...
(Date:9/23/2014)... Sept. 23, 2014 (HealthDay News) -- The number ... prescription drugs is growing, so doctors need to ... and Drug Administration warned Tuesday. In a ... widespread that it has launched a program to ... administrators about proper drug purchasing procedures. The program ...
(Date:9/23/2014)... are already obese as teenagers could grow up to ... of normal weight. So says Petter Lundborg of Lund ... of Linneas University and Lund University, all in Sweden. ... Kingdom and the United States, and the results are ... The researchers analyzed large-scale data of 145,193 Swedish-born brothers ...
(Date:9/23/2014)... Both patients and healthcare professionals believe diagnosis of ... greatly outweighs the potential disadvantages of subsequent radiologic ... according to a new study published in the ... , Diagnostic tests used for cancer screening programs ... for colorectal cancer with CT colonography, abdominal and ...
Breaking Medicine News(10 mins):Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3
... of New Molecular Entities Drops to Historic Low ... Face Increasing Competition from ... Scientific business of Thomson,Reuters today announced the availability ... Factbook, an indispensable reference,and business planning tool for ...
... welcome to out-of-state intended parents, SAN RAMON, ... decision to allow gay couples to marry strengthens ... Bay Area (RSC), one of,the state,s leading fertility ... "California,s legalization of same-sex marriage supports RSC,s,long-held ...
... for Immigration and Naturalization ready at Passport ... ... New vaccine requirements will affect,anyone who is applying for an ... status for permanent residence. Applicants,must show proof of vaccinations against vaccine-preventable ...
... Excessive IMP-3, not found in harmless moles, may be key ... produces high levels of a protein called IMP-3, which is ... researchers report. , They said the finding may offer doctors ... type of skin cancer -- from benign moles that look ...
... The American Heart,Association announces the call for ... association,s highest honor for health and science,reporting., ... and honor the career,achievements of science, health and ... in the fight against heart disease and,stroke. This ...
... County,Place Matters Team will host a three-day meeting July ... that lead to poor health outcomes,in individuals from low-income ... cities and counties will attend. Place Matters,is a national ... Health Policy Institute and is funded by the W. ...
Cached Medicine News:Health News:Thomson Reuters Publishes CMR International's 2008 Pharmaceutical R&D Factbook, Now Available for the First Time Online 2Health News:California Supreme Court Gay-Marriage Ruling Reinforces Top Bay Area Fertility Specialists' Support for Same-Sex Couples 2Health News:USCIS Tightens Vaccination Requirements 2Health News:Protein Gives Doctors New Tool to Detect Melanoma 2Health News:Alameda County Hosts National Initiative to Reduce Health Disparities 2
... Retinol binding Proetin (RBP) is small ... a complex with pre-albumin in blood but ... has been deliverd to the target cells. ... at the glomerulus and catabolized in the,renal ...
... is an enzyme immunoassay (EIA) kit for ... of the subclass of Anti-Neutrophil Cytoplasmic Antibodies ... as an aid in the diagnosis of ... associated with vasculitic disorders and glomerulonephritis (GN). ...
Anti-MPO ANCA EIA Auto-Immune Markers 013-MPO-96 Myeloperoxidase...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
Medicine Products: